Teva Pharmaceuticals logo
|Traded as||TASE: TEVA|
Israel Parsippany, New Jersey U.S. (commercial)
|Revenue||US$18.9 billion (2018)|
Number of employees
Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), also known as Teva Pharmaceuticals, is an American Israeli pharmaceutical company with dual headquarters in Petah Tikva, Israel (global) and Parsippany, New Jersey, U.S. (commercial). It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.
Teva's facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Founding of Salomon, Levin, and Elstein
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem, then part of Ottoman Syria, that was founded in 1901, and used camels to make deliveries. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva ("nature" in Hebrew) and Zori. In the 1930s, Salomon, Levin, and Elstein Ltd. also founded Assia, a pharmaceutical company.
Founding of Teva Pharmaceutical Industries
Teva Pharmaceutical Industries was founded by Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem. Friedländer was a German pharmacist, botanist and pharmacognos, who immigrated to Mandatory Palestine in 1934, following the Nazi Party Rise to power.
The company was built with an investment of 4,900 pounds sterling, which came from the family's own capital and partly from loans from other German immigrants. Capital shortage led to the joining of the banker Alfred Feuchtwanger as a partner in Teva, who received 33% of the shares in return for his investment. In 1951, Feuchtwanger initiated an initial public offering to raise capital through the newly founded Tel-Aviv Stock Exchange, and Teva became a public company.
Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In the Second World War, the company provided medicine to the allied forces and in particular to the British army present in the Middle East. After the war, Sir Alan Gordon Cunningham, the last of the High Commissioners for Palestine and Transjordan, visited Teva on behalf of the Secretary of State for the Colonies. His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development.
During the Second World War and until the termination of the British Mandatory Palestine regime, Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in an exhibition held in Cairo, Egypt. The exhibition was sponsored by the General Agent and Sole Distribution of medicine in Egypt and Sudan, Syria and Lebanon. Later on, Teva exported its products to the US, Soviet Union (USSR), health institutes in Denmark, Czechoslovakia, Persia and Burma.
In 1954, Teva received a Certificate Excellence in Training award from the Israeli President, Yitzhak Ben Zvi. In 1964, Teva partnered with Sintex, a company from Mexico, and Schering Plough.
Merger of Assia, Zori and Teva
In 1964, Assia and Zori merged and in 1968 acquired a controlling stake in Teva. In 1976, the three companies merged into the modern-day Teva Pharmaceutical Industries Ltd. In 1980, Teva acquired Ikapharm, then Israel's second largest drug manufacturer.
1980 to 1999
2000 to 2009
In October 2003, Teva announced its intentions to acquire Sicor Inc. for $3.4 billion. Following the announcement, the acquisition was completed on January 22, 2004, which marked Teva's entry into biosimilars' market.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.
In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. Teva acquired its U.S. rival Ivax Corporation in January 2006, Barr in 2007 and Ratiopharm in 2010. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.
On March 18, 2010, Teva said it planned to acquire German generic Ratiopharm for US$5 billion. The deal was completed in August 2010. In May 2011, Teva bought Cephalon for US$6.8 billion. The same month, Teva announced the ¥40 billion purchase of a majority stake in Japanese generic drug company Taiyo Pharmaceutical Industry, a move to secure a Japan-local production facility. Teva completed the $934 million acquisition in July 2011. In June 2013, Teva acquired US firm MicroDose Therapeutx for $40 million with as much as $125 million being paid in regulatory and developmental milestones  In 2010, Teva announced that it would build its main distribution center for the Americas in Philadelphia, PA, and was considering opening its US headquarters in the area. In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774. In March 2010, Teva acquired German-based company Ratiopharm in a deal worth almost $5 billion, significantly expanding its European coverage. In October 2010, Teva entered a licensing agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 billion in funding from Israel's Office of the Chief Scientist.
In January 2014, Teva acquired NuPathe, after outbidding Endo, for $144 million. In June 2014, Teva acquired Labrys Biologics for up to $825 million, the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti-CGRP monoclonal antibody therapeutic.
In March 2015, Teva acquired Auspex Pharmaceuticals for $3.5 billion growing its CNS portfolio. In April, Teva offered to acquire Mylan for $40 billion, only a fortnight after Mylan offered to buy Perrigo for $29 billion. Teva's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo. Mylan stated in June 2015 that Teva's disclosure that it had a 1.35 percent stake in Mylan violated US antitrust rules. In October, the company acquired Mexico-based Representaciones e Investigaciones Medicas (Rimsa) for around $2.3 billion. In the same month Teva acquired Gecko Health Innovations. In November 2015, the company announced it would collaborate with Heptares Therapeutics with its work on small-molecule calcitonin gene-related peptide antagonists for migraine treatment, with the deal generating up to $410 million.
Teva Active Pharmaceutical Ingredients (TAPI) operates within Teva as a stand-alone business unit. In 2009, TAPI's sales to third parties totaled $565 million, and in 2010 sales rose by 13% to a total of $641 million.
In July 2017, it was reported that Pascal Soriot, CEO of AstraZeneca since 2012, would become the next CEO of Teva, succeeding Erez Vigodman, however this was soon refuted. As of August 2017, the company has struggled to attract a new CEO, leading to mounting questions for the board. In August 2017, the board of directors announced a 75% cut in the dividend, reflecting declining profitability, and the share price fell by almost half in the days following. As of September 11, 2017, Teva remained the “world’s biggest seller of generics medicines.” On September 11, 2017, it was reported that they had selected Kåre Schultz as the new Teva CEO. A day later the company announced it would sell its Paragard contraceptive brand to Cooper Cos for $1.1 billion, with the funds being used to pay down debt. Days later the company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million and its emergency contraception brands for $675 million to Foundation Consumer Healthcare. By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy. Following considerable lobbying by the Israeli Government, from whom Teva received considerable tax breaks, and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel.
In October 2019 Teva faced criticism for making a “business decision to discontinue the drug” Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.
In July 2015, Allergan agreed to sell its generic drug business (Actavis Generics) to Teva for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares). As a result, Teva dropped its pursuit of Mylan. In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $40 million, as well as a further eight medicines to Dr. Reddy's in a $350 million deal. Teva also sold a further 15 marketed generics, as well as three others which were close to market, for $586 million to Impax Laboratories. In July, Teva sold off a further 42 products to Australian generics company, Mayne Pharma, for $652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies. As part of the deal Teva will seek to raise $20 to $25 billion through a bond sale.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|Teva Pharmaceutical Industries||
On October 21, 2011, Par Pharmaceutical has sealed the deal to three products from Teva Pharmaceutical Industries, which the Israeli firm was required by the US Federal Trade Commission to divest before it could acquire US biotech Cephalon for $6.8 billion.
Following the acquisition of Allergan plc generic division some assets have sold off to meet US antitrust requirements. In June 2016 Indian pharmaceutical company Dr. Reddy's Laboratories Ltd bought 8 (ANDA) Abbreviated New Drug Applications for $350 million in cash. Also in June 2016 Teva sold two abbreviated new drug applications (ANDAs) to Indian pharmaceutical company Zydus Cadilla strengthen its US portfolio. On June 21, 2016, American pharmaceutical company Amneal Pharmaceutical previously known as Impax Laboratories bought a portfolio of generic drugs from Teva Pharmaceutical Industries for about $586 million. On July 29, Cipla an Indian pharmaceutical company bought three products from Teva. Indian pharmaceutical company, Aurobindo, was in the race to buy some Teva assets. In October 2016, Teva has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds (5083 crore Indian rupees)in cash. In August 2016, Australia pharmaceutical company Mayne Pharmaceutical bought a portfolio of drugs from pharmaceutical giant Teva Pharmaceuticals last year for $845 million Australian dollars. In February 2018, Teva Pharmaceutical Industries Ltd has completed the sale of a portfolio of products within its global women's health business across contraception, fertility, menopause and osteoporosis for $703 million in cash to CVC Capital Partners Fund VI. Teva also agreed to sell its Plan B One-Step and its brands of emergency contraception to Foundation Consumer Healthcare for $675 million in cash. Combined annual net sales of these products were $140 million last year. It also sold Paragard to a unit of Cooper Companies Inc (COO.N) for $1.1 billion.
|Chief Executive Officer||Period of office||Notes|
|Eli Hurvitz||1976 to 2002||CEO & Chairman of the board until his death in 2011.|
|Israel Makov||2002 to 2007|||
|Shlomo Yanai||March 2007 to May 2012||Announced his resignation at the beginning of 2012.|
|Jeremy Levin||May 2012 to October 2013|||
|Eyal Desheh||October 2013 to January 2014||Interim CEO|
|Erez Vigodman||January 2014 to February 2017||Desheh returned to previous position of chief financial officer. Vigodman served as the CEO of Makhteshim Agan until joining Teva, and was president and CEO of Strauss Group prior to this. From 2014, Michael Hayden served as Teva's chief scientific officer and president of the company's global research and development.|
|Yitzhak Peterburg||February 2017 to Sept 2017||Peterburg held the position of Chairman since 2015. He was appointed as Interim President and CEO in 2017 succeeding Erez Vigodman. Since Israeli law does not permit the same individual to serve as CEO and Chairman, Sol J Barer took over as the Chairman of the board in February 2017.|
|Kåre Schultz||September 2017 – present||Schultz was appointed as the CEO and President succeeding the acting president and CEO Yitzhak Peterburg.|
Research and development
Teva holds patents on multiple drugs, including: Copaxone, a specialty drug (for the treatment of multiple sclerosis), now the world's best selling MS drug, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease. By July 2015, Copaxone held a "31.2 percent shares of total MS prescriptions in the United States." Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States." Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue." Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.
In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently[when?] competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
- CEP-32496 (renamed RXDX-105) a small molecule inhibitor of BRAF, EGFR and RET, now in Phase I/II trials
- CEP-40783 (renamed RXDX-106) a small molecule inhibitor of AXL and c-Met in preclinical development
- CEP-40125 (renamed RXDX-107) a nanoformulation of a modified bendamustine with potenital activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's specialty drugs pipeline.
- TEV-44229 (renamed RXDX-108) a potent inhibitor of the kinase PKCiota
In July 2019, the company stopped production of Vincristine, a critical drug used to treat the most common forms of childhood cancer, and was criticized by media for creating a worldwide shortage of the drug. On 28 January 2020, the company announced that the Food and Drug Administration (FDA) had approved an autoinjector device for Ajovy (fremanezumab-vfrm) injection.
On June 25, 2010, Bayer sued Teva for falsely claiming that Gianvi, Teva's Generic of Yaz, was "stabilized by betadex as a clathrate." The lawsuit stems from Bayer's US patent, 5798338, on the binding and preservative agents that were not in fact present in Gianvi. "In the preparation of such low-dosed dosage forms, strong fluctuations of the active ingredient concentrations in the dosage units occur almost unavoidably (inadequate content uniformity), which manifest themselves more strongly, the smaller the amount of the active ingredient. It has now been found that the drawbacks that are observed especially in the preparation and storage of dosage forms which contain low-dosed steroidal sex hormones can be avoided, at least to a large extent, if dosage forms are prepared that contain powdery cyclodextrin clathrates of these active ingredients." The settlement of the lawsuit resulted in Teva changing its product marketing to remove the claim that it used the same ingredients as Yaz. Bayer's patent is on a method specifically designed to prevent oxidative degradation of the estrogen.
In December 2016, the attorneys general of 20 states filed a civil complaint accusing Teva of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.
In January 2019, the Supreme Court of the United States decided for Teva in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc.
In May 2019, Teva Pharmaceuticals USA was one of 19 drug companies sued for price fixing in the United States by 44 states for inflating its prices, sometimes up to 1000%, in an illegal agreement among it and its competitors. Also in May 2019, Teva Pharmaceuticals USA agreed to pay $85 million to the U.S. state of Oklahoma to settle an opioid over prescription lawsuit.
In July 2019, Teva paid $69 million to settle pay-for-delay claims.
A full list of products is available from www.tevagenerics.com.
- Adderall (generic and branded)
- Amikacin Sulfate
- Aripiprazole (generic)
- Augmentin (generic)
- Bisoprolol Fumarate
- Doxorubicin HCl
- Epirubicin HCl
- Epoprostenol Sodium
- Haloperidol Decanoate
- Hydroxyzine Hydrochloride
- Ibuprofen Max
- Idarubicin HCl
- Leucovorin Calcium
- Levonorgestrel branded as Enpresse
- Loperamide 2mg
- Montelukast (generic) 
- Naproxen
- Salbutamol (Albuterol)
- Sulfamethoxazole Trimethoprim
- Economy of Israel
- Health care in Israel
- Opioid epidemic in the United States
- Science and technology in Israel
- Teva Active Pharmaceutical Ingredients (TAPI)
- "Teva Pharmaceuticals Moving U.S. Headquarters To New Jersey". businessfacilities.com. Retrieved November 28, 2019.
- "TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Israel Company Reports – Search Israeli Companies". www.israelbizreg.com. Retrieved October 19, 2016.
- Hollis, Liz Jones (August 10, 2010). "Teva – Top 10 Generic Drug Companies 2010". FiercePharma. Washington, DC, United States: FierceMarkets. Archived from the original on May 8, 2011. Retrieved November 3, 2010.
- "Teva Pharmaceutical Industries—Jerusalem". Database. Jerusalem, Israel: BioJerusalem. Archived from the original on July 21, 2011.
- "Teva wins controversial PhRMA bid despite protests from branded rivals – FiercePharma". www.fiercepharma.com. Retrieved May 23, 2017.
- "Teva, one of the biggest generic makers, joins the brand-name club". STAT. July 18, 2016. Retrieved August 20, 2017.
- Kiliç, Burcu (July 31, 2014). Boosting Pharmaceutical Innovation in the Post-TRIPS Era. Edward Elgar Publishing. ISBN 9781782544135. Retrieved May 23, 2017 – via Google Books.
- Specht, Heike (October 24, 2013). Die Feuchtwangers: Familie, Tradition und jüdisches Selbstverständnis. Wallstein Verlag. ISBN 9783835306639. Retrieved February 21, 2019 – via Google Books.
- Benari, Elad (November 22, 2011). "Former CEO of Teva Pharmaceuticals Dies at 79 - Inside Israel". Israel National News. Retrieved April 21, 2020.
- "Archived copy". Archived from the original on March 17, 2007. Retrieved March 17, 2007.CS1 maint: archived copy as title (link) The History of Teva
- Odagiri, Hiroyuki; Goto, Akira; Sunami, Atsushi; Nelson, Richard R. (April 8, 2010). Intellectual Property Rights, Development, and Catch Up: An International Comparative Study. OUP Oxford. p. 234. ISBN 978-0-19-957475-9.
- "Teva — Plantex Limited". tapi.com.
- "TEVA NOVOPHARM — Novopharm Limited becomes Teva Canada Limited". newswire.ca.
- Jerry Hirsch (November 1, 2003). "Drug Maker Teva to Buy Sicor". Los Angeles Times.
- "Teva Completes Acquisition of Sicor". January 22, 2004. Archived from the original on January 7, 2018. Retrieved January 6, 2018.
- Singer, Natasha (March 18, 2010). "Teva to Acquire Top German Generics Maker for $5 Billion". The New York Times. Retrieved March 18, 2010.
- Grogan, Kevin (May 5, 2011). "Teva plans $500 million Japan acquisition". PharmaTimes Magazine. London, England. Online PharmaTimes. Archived from the original on May 7, 2011. Retrieved May 7, 2011.
- "Kowa, Teva to form generic drug venture". The Japan Times Online. September 25, 2008. Retrieved August 20, 2017.
- "Archived copy". Archived from the original on November 7, 2014. Retrieved November 7, 2014.CS1 maint: archived copy as title (link)
- Schmit, Julie (July 26, 2005). "USATODAY.com — Teva Pharmaceuticals to buy Ivax in $7.4 billion deal". usatoday.com.
- Jennifer Bayot for the New York Times. July 26, 2005 Teva to Acquire Ivax, Another Maker of Generic Drugs
- Teva Press Release, 2006. Teva Completes Acquisition of Ivax
- "Teva Completes Acquisition of Barr". tevapharm.com. Archived from the original on January 24, 2009.
- Nicholson, Chris V. (May 2, 2011). "Teva to Buy Cephalon for $6.8 Billion". The New York Times.
- "Teva completes $934m Taiyo acquisition". Globes.co.il. July 14, 2011.
- Wainer, David (June 17, 2013). "Teva Adds MicroDose to Respiratory Business in $165 Million Deal". Bloomberg.com.
- Yeshayahou, Koby (February 16, 2011). "Teva employees gain $222m on options". Globes. Rishon Le-Zion, Israel: Globes Publisher Itonut. globes-online.com. Archived from the original on May 8, 2011.
- Ravoos Laboratories
- Jonathan D. Rockoff; Eyk Henning (March 19, 2010). "Teva to Acquire Generics Firm". The Wall Street Journal. New York City. WSJ.com. Archived from the original (~100 words) on May 9, 2011. Retrieved May 8, 2011.
- Robert Daniel; Polya Lesova (March 18, 2010). "Teva to acquire Ratiopharm in deal valued near $5 billion". MarketWatch. New York City: Dow Jones & Co. Archived from the original on May 9, 2011. Retrieved May 8, 2011.
- "Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd". businesswire.com. October 11, 2010.
- "BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist". businesswire.com. May 13, 2013.
- Nicholson, Chris V. (May 2, 2011). "Teva to Buy Cephalon for $6.8 Billion". The New York Times. Retrieved April 21, 2020.
- "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10.
- Staff (June 3, 2014). "Teva Buys Labrys, Growing Pain Franchise in Up to $825M Deal". Genetic Engineering & Biotechnology News. Retrieved July 21, 2014.
- George, John (July 21, 2014). "Teva completes deal for second migraine-treatment developer". Philadelphia Business Journal. Retrieved July 21, 2014.
- Staff (March 30, 2015). "Teva to Acquire Auspex for $3.5B, Growing CNS Portfolio". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- Staff (April 21, 2015). "Teva Offers to Buy Mylan for $40B". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- Staff (April 8, 2015). "Mylan Offers $28.9B for Perrigo". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- "Teva Offers to Buy Mylan in $40.1B Cash-And-Stock Deal". Pharmaceutical Processing. Associated Press. April 21, 2015. Retrieved April 21, 2015.
- Rao Koppala, Anjali (June 1, 2015). "Mylan says Teva's stake buy violates U.S. antitrust rules". Reuters. Retrieved June 2, 2015.
- "Teva beefs up in emerging markets with $2.3B Rimsa buyout". FiercePharma.com.
- "Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds". FiercePharma.com.
- "Teva, Heptares Launch Up-to-$410M+ Migraine Alliance". GEN Eng News. November 25, 2015.
- "AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report". Reuters. May 14, 2014. Retrieved July 12, 2017.
- "Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva – ENDPOINTS NEWS". Endpts.com. Retrieved July 12, 2017.
- Boland, Hannah (July 14, 2017). "Pascal Soriot looks set to stay as AstraZeneca chief". The Daily Telegraph. Retrieved May 15, 2018.
- Jones, Rory (August 7, 2017). "Teva Pharmaceutical Industries faces high price for new chief". The Wall Street Journal. Retrieved August 6, 2017.
- "Teva Reports Second Quarter 2017 Financial Results". corporate-ir.net (Press release). Teva. August 3, 2017. Retrieved August 8, 2017.
- "Teva stock price chart". Google Finance. Retrieved August 8, 2017.
- Jones, Rory (September 11, 2017). "Teva Appoints New Chief Executive After Months of Speculation". Wall Street Journal. New York City, New York. Retrieved September 11, 2017.
- "Teva to sell contraceptive brand Paragard in $1.1 billion deal". Reuters. September 11, 2017. Retrieved February 21, 2019.
- "Teva finishes women's health sale with deals worth $1.38B". fiercepharma.com. Retrieved February 21, 2019.
- Barber, Joe (December 14, 2017). "Teva to cut over 25 percent of global workforce". First Word Pharma Plus. Doctor's Guide Publishing Limited. Retrieved February 9, 2018.
- Schindler, Max (December 22, 2017). "Economy Minister: Teva Should Earn Its Tax Breaks". Jerusalem Post.
- Weinreb, Gali (January 1, 2018). "Teva Dewlays 33% of Jerusalem Layoffs Until 2019". Jerusalem Post.
- The New York Times, "Faced with a Drug Shortfall, Doctors Scramble to Treat Children with Cancer," Oct 28, 2019 
- ABC News, "Shortage of critical cancer drug forcing some children to go without," Oct 22, 2019 
- "Analyst cuts Allergan generics sales estimates as Teva deal close nears". FiercePharma.com.
- "Teva to Buy Allergan's Generic Drug Unit". Bloomberg.com. July 27, 2015.
- Cynthia Koons (July 27, 2015). "Teva CEO: $40.5 Billion Allergan Deal is Just the Beginning - Bloomberg Business". Bloomberg.com.
- "Teva Purchasing Allergan's Generics Unit in $40.5B Deal". Bloomberg.com. July 27, 2015.
- Somayaji, Chitra (July 27, 2015). "Teva Snaps Up Allergan's Generics Arm, Dumping Mylan". Bloomberg.com.
- "Impax Buys Generic Product Portfolio from Teva, Allergan for $586M". GEN Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. June 21, 2016.
- "Teva sells castoffs to Impax for $586M as clock ticks on Allergan deal". FiercePhama.com.
- "Mayne vaults ahead in U.S. with $652M deal for Teva/Allergan meds". FiercePharma.com.
- "Teva looks for $20B-plus from bond sale to finance Allergan deal". FiercePharma.com.
- "Form 6-K". SEC.gov. Securities & Exchange Commission.
- "After Completing $39B Acquisition, Teva Does Another Generics Deal with Allergan". GEN Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. August 3, 2016. Retrieved May 23, 2017.
- "Par acquires Teva's divested ANDAs, and is already shipping fentanyl citrate". Scrip. October 21, 2011. Retrieved May 27, 2019.
- "Teva Completes Acquisition of Actavis Generics". tevapharm.com. Retrieved May 27, 2019.
- "India's Dr Reddy's in $350 million deal to buy eight U.S. drugs..." Reuters. June 11, 2016. Retrieved May 27, 2019 – via www.reuters.com.
- "Zydus Cadila acquires two drugs from Teva to strengthen US portfolio". VCCircle. June 20, 2016. Retrieved May 27, 2019.
- "Impax Buys Generic Drugs from Teva and Allergan for $586 Million". Fortune. Retrieved May 27, 2019.
- "Cipla, Aurobindo Pharma to acquire drugs from Teva". VCCircle. July 29, 2016. Retrieved May 27, 2019.
- Balakrishnan, Swaraj Singh Dhanjal,Reghu (October 5, 2016). "Intas Pharma to buy Teva's UK, Ireland generics businesses". Mint. Retrieved May 27, 2019.
- "Mayne Pharma profit soars on Teva deal". Australian Financial Review. February 23, 2017. Retrieved May 27, 2019.
- "Teva Announces Completion of Global Women's Health Divestiture to CVC Capital Partners". www.businesswire.com. February 1, 2018. Retrieved May 27, 2019.
- "Teva Pharma to sell more women's health assets for $1.38 billion". Reuters. September 18, 2017. Retrieved May 27, 2019 – via www.reuters.com.
- "Teva Pharmaceutical Industries Ltd (TEVA.O) Officers". Reuters. Archived from the original on September 29, 2008. Retrieved October 11, 2008.
- Coren, Ora (February 21, 2008). "Most respected managers in market: Tshuva, Dankner, Maor and Hurvitz". Haaretz. Archived from the original on October 20, 2012. Retrieved March 21, 2014.
- Teva Pharmaceuticals Inc. (February 14, 2002). "Teva news release hiring Israel Makov". Retrieved September 28, 2014.
- Golan Hazani. (October 18, 2006). "Ynet reports Israel Makov resignation". Retrieved September 28, 2014.
- "Teva CEO Shlomo Yanai leaving in May, to be replaced by American". Haaretz. Retrieved December 7, 2013.
- "Teva CEO Jeremy Levin steps down". Globes. Archived from the original on November 4, 2013. Retrieved October 30, 2013.
- "Teva Names a New Chief Executive". Business Day. The New York Times. Bloomberg News. January 2, 2012. Archived from the original on April 27, 2012. Retrieved January 3, 2012.(registration required)
- "Israel's Teva Pharm names Vigodman as CEO". Reuters. January 9, 2014. Archived from the original on January 9, 2014.
- "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
- "Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman" (PDF).
- Jones, Rory (September 11, 2017). "Teva Appoints New Chief Executive After Months of Speculation". Wall Street Journal. ISSN 0099-9660. Retrieved September 12, 2017.
- Scheer, Steven; Jacobsen, Stine (September 11, 2017). "Drugmaker Teva hires Lundbeck CEO Schultz to restore its health". Reuters. Retrieved September 12, 2017.
- "Our Specialty Pipeline". Teva Pharmaceutical Industries. nd. Retrieved October 16, 2015.
- "Teva's MS drug Copaxone has strong second-quarter sales". Reuters. Jerusalem, Israel. July 2015. Retrieved October 16, 2015.
- "Teva won't make more of powerful sedative". May 28, 2010.
- "GEN — News Highlights:Ignyta Buys Four Cancer Compounds from Teva". GEN. March 18, 2015.
- Rabin, Roni Caryn (October 14, 2019). "Faced With a Drug Shortfall, Doctors Scramble to Treat Children With Cancer". The New York Times.
- "Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector". www.tevapharm.com. Retrieved February 14, 2020.
- Bayer HealthCare Pharmaceuticals Inc. (June 25, 2010). "Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Teva's Generic Oral Contraceptive Gianvi". Archived from the original on January 3, 2011. Retrieved December 26, 2010.
- Backensfeld; et al. (August 25, 1998). "Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol". Archived from the original on December 20, 2016. Retrieved December 26, 2010.
- Maureen M Cavanaugh, Teva Pharmaceuticals (July 1, 2010). "Microsoft Word – Gianvi Pharmacist Letter – RevD – Final 7-1-10 – web versi..." (PDF). Archived from the original (PDF) on March 14, 2012. Retrieved December 26, 2010.
- "Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc". SCOTUSblog. Retrieved January 27, 2015.
- Thomas, Katie (December 15, 2016). "20 States Accuse Generic Drug Companies of Price Fixing". The New York Times. Retrieved December 16, 2016.
- "Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc". SCOTUSblog. Retrieved February 21, 2019.
- "Drugmakers allegedly inflated prices over 1,000% and 44 states are now suing". CNBC. May 11, 2019. Retrieved May 12, 2019.
- "Johnson & Johnson in billion-dollar opioid trial". May 28, 2019. Retrieved May 31, 2019.
- "Three drugmakers settle with California over deals to keep generic medications off the market". Los Angeles Times. July 29, 2019.
- Mfg. by Watson Pharmaceuticals. See Actavis Acquisition and Watson Name Change, and Allergan, Inc. Acquisition and Actavis, plc Name Change
- DeNoon, D. (August 3, 2012). Generic singulair approved. Retrieved from http://www.webmd.com/asthma/news/20120803/generic-singulair-approved
- "Teva Announces Launch Of Generic Protonix Tablets". tevapharm.com. Archived from the original on December 29, 2007.
- "Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry". 2018.
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen.